Status:
UNKNOWN
Oral Ibuprofen Prophylaxis for Patent Ductus Arterioses in Very Extremely Low Birth Weight Infants
Lead Sponsor:
Zekai Tahir Burak Women's Health Research and Education Hospital
Conditions:
Oral Ibuprofen Prophylaxis in Very Low Birth Weight Infants
Eligibility:
All Genders
23-28 years
Phase:
NA
Brief Summary
Patent ductus arterioses (PDA) is a major morbidity in preterm infants, especially in extremely premature infants less than 28 weeks. The clinical signs and symptoms of PDA in preterm infants are non ...
Detailed Description
Patent ductus arterioses (PDA) is a major morbidity encountered in preterm neonates, especially in babies less than 28 weeks gestation or 1000g.Natural ductal closure is inversely related to gestation...
Eligibility Criteria
Inclusion
- \< 28 gestational week and/or \< 1000 g birth weight preterm infants written parent consent
Exclusion
- major congenital anomalies
- congenital heart diseases
- not having written parent consent
Key Trial Info
Start Date :
July 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2012
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01400737
Start Date
July 1 2011
End Date
July 1 2012
Last Update
July 22 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zekai Tahir Burak Maternity Teaching Hospital
Ankara, Turkey (Türkiye)